Evidence map›Paper›PMID 40225586›Full record

ArticleTheranostics2025

EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment.

Ajay Kumar Sharma, Kuldeep Gupta, Akhilesh Mishra, Gabriela Lofland, Sophia Y Chen, Ian Marsh, Peyton T Fair, Robert F Hobbs, Todd M Armstrong, Elizabeth M Jaffee and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Progress in the application ofAnnals of nuclear medicine · 2026
    Review
  5. Review
  6. Article
  7. [Npj imaging · 2026
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Development of aCellular oncology (Dordrecht, Netherlands) · 2025
    Article
  13. The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ajay Kumar SharmaThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Kuldeep GuptaThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Akhilesh MishraThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Gabriela LoflandThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Sophia Y ChenDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Ian MarshThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Peyton T FairDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Robert F HobbsThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Todd M ArmstrongDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Elizabeth M JaffeeDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Edward W GabrielsonDepartment of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Lei ZhengDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Sridhar NimmagaddaThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Non-invasive Quantification of Dose-Exposure-Response of PD-L1 Therapeutics at the TumorR01CA236616 · NCI · JOHNS HOPKINS UNIVERSITY · PI NIMMAGADDA, SRIDHAR · 2018 to 2022
$2.3M
NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA236616
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alpha ParticlesCarcinoma, Pancreatic DuctalPancreatic NeoplasmsReceptor, EphA2Theranostic NanomedicineAnimalsCell Line, TumorGallium RadioisotopesHumansMiceMice, NudePositron-Emission TomographyPrecision MedicineRadiopharmaceuticalsXenograft Model Antitumor AssaysEPHA2 protein, humanGallium-68Gallium RadioisotopesRadiopharmaceuticalsReceptor, EphA2Alpha-particle therapyGallium-68ImagingPancreatic cancerPeptide radiopharmaceuticalsPETRadiotherapy

Identifiers

PMID40225586
PMCPMC11984392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.